Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded related topics to the page: Lung cancer and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check10 days agoNo Change Detected
- Check31 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference4%

- Check39 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check46 days agoChange Detected- The page now removes MedlinePlus Genetics coverage related to Lung cancer, narrowing the topic scope without adding new content.SummaryDifference0.3%

- Check53 days agoChange DetectedAdds Lung cancer topic under MedlinePlus Genetics and updates to v3.0.2; removes the Back to Top element and the old v3.0.1 revision.SummaryDifference0.5%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.